Methenamine Hippurate Pfleger (Methenamine Hippurate)

When methenamine hippurate reaches acidic urine (pH below 6), it hydrolyses to release formaldehyde and ammonia. Formaldehyde acts as a broad‑spectrum bactericidal agent, disrupting bacterial proteins and nucleic acids, thereby inhibiting the growth of common urinary pathogens while the parent compound remains inactive at neutral pH.

The appropriate dose of Methenamine Hippurate Pfleger is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function and urine pH. Dosage regimens may vary, and the prescriber will provide specific instructions tailored to each individual.

Safety data for methenamine hippurate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methenamine hippurate differs from agents such as nitrofurantoin or trimethoprim‑sulfamethoxazole in that it requires an acidic urinary environment to become active, producing formaldehyde locally. This mechanism can be advantageous for patients who need a non‑systemic prophylactic option, though it may be less effective if urine pH is alkaline.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture and direct sunlight. No refrigeration is required, but keep the container tightly closed to maintain product stability.

The medication is taken orally, usually with a full glass of water. It is important to maintain an acidic urinary environment, so patients may be advised to avoid alkaline foods or drinks and to follow any additional dietary recommendations provided by their clinician.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, significant hematuria unrelated to irritation, and acute kidney injury in patients with pre‑existing renal disease. Immediate medical attention is required if any of these occur.

Methenamine hippurate should be avoided in individuals with known hypersensitivity to the drug, in patients with alkaline urine (pH ≥ 7) where activation is impaired, and in those with severe renal impairment where drug clearance is markedly reduced. Consultation with a healthcare professional is essential before use.